• Maia Biotechnology opened enrollment at a second US site for its Phase 2 THIO-101 expansion trial in third-line non-small cell lung cancer.
• No new results were presented; additional expansion data are expected in future interim updates to support a potential FDA accelerated approval filing.
• The study evaluates ateganosine in patients who failed checkpoint inhibitors and chemotherapy, aiming to show clinically meaningful benefit without detailing metrics.
• Maia is also screening patients for a pivotal Phase 3 overall-survival study comparing ateganosine sequenced with a CPI versus investigator’s-choice chemotherapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief on June 10, 2026, and is solely responsible for the information contained therein.